drugset / Trial / NCT06210646

Citicoline in Ischemic Stroke, a Randomized Trial

NCT06210646

Phase 3 Completed 800 enrolled Kafrelsheikh University
RandomizedParallel-groupDouble-blindTreatment

Summary

Along with the current clinical trial, the efficacy and safety of a 2000 mg daily citicoline administered within 24 hours of the first-ever ischemic stroke and lasted 12 months compared to 1000 mg were assessed through MoCA, NIHSS, mRS, and possible adverse effects.

Timeline

Start
2022-12-29
Primary completion
2024-06-29
Completion
2024-06-29

Drugs

EvaluationDrugModalityDoseRoute
Comparator Citicoline Other / unclassified 1000 mg
Comparator Citicoline Other / unclassified 2000 mg

Indications